← Back to Screener
Cellectis S.A. American Depositary Shares (CLLS)
Price$4.10
Favorite Metrics
Price vs S&P 500 (26W)-11.77%
Price vs S&P 500 (4W)17.85%
Market Capitalization$273.53M
All Metrics
P/CF (Annual)10.79x
Book Value / Share (Quarterly)$1.05
P/TBV (Annual)4.68x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)45.72%
Cash Flow / Share (Quarterly)$-0.59
Price vs S&P 500 (YTD)-13.21%
Gross Margin (TTM)43.61%
Net Profit Margin (TTM)-66.10%
EPS (TTM)$-0.85
10-Day Avg Trading Volume0.66M
EPS Excl Extra (TTM)$-0.85
Revenue Growth (5Y)5.97%
EPS (Annual)$-0.67
ROI (Annual)-36.47%
Gross Margin (Annual)43.61%
Net Profit Margin (5Y Avg)-393.48%
Cash / Share (Quarterly)$2.88
Revenue Growth QoQ (YoY)48.64%
ROA (Last FY)-20.82%
Revenue Growth TTM (YoY)74.59%
EBITD / Share (TTM)$-0.19
ROE (5Y Avg)-75.60%
Operating Margin (TTM)-30.45%
Cash Flow / Share (Annual)$-0.59
P/B Ratio4.24x
P/B Ratio (Quarterly)4.65x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.87x
Net Interest Coverage (TTM)-0.95x
ROA (TTM)-24.57%
EPS Incl Extra (Annual)$-0.67
Current Ratio (Annual)1.62x
Quick Ratio (Quarterly)1.61x
3-Month Avg Trading Volume0.32M
52-Week Price Return181.40%
EV / Free Cash Flow (Annual)8.19x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.04
P/S Ratio (Annual)4.04x
Asset Turnover (Annual)0.25x
52-Week High$4.84
Operating Margin (5Y Avg)-367.53%
EPS Excl Extra (Annual)$-0.67
CapEx CAGR (5Y)-41.81%
Tangible BV CAGR (5Y)-22.75%
26-Week Price Return-3.03%
Quick Ratio (Annual)1.61x
13-Week Price Return5.64%
Total Debt / Equity (Annual)1.44x
Current Ratio (Quarterly)1.62x
Enterprise Value$369.674
Revenue / Share Growth (5Y)-10.75%
Asset Turnover (TTM)0.37x
Book Value / Share Growth (5Y)-30.44%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)82.27x
Pretax Margin (Annual)-85.46%
Cash / Share (Annual)$2.88
3-Month Return Std Dev64.46%
Gross Margin (5Y Avg)-84.99%
Net Income / Employee (TTM)$-0
ROE (Last FY)-89.05%
Net Interest Coverage (Annual)-0.85x
EPS Basic Excl Extra (Annual)$-0.67
P/FCF (TTM)6.55x
Receivables Turnover (TTM)12.20x
Total Debt / Equity (Quarterly)1.44x
EPS Incl Extra (TTM)$-0.85
Receivables Turnover (Annual)7.54x
ROI (TTM)-43.24%
P/S Ratio (TTM)2.50x
Pretax Margin (5Y Avg)-412.20%
Revenue / Share (Annual)$0.79
Tangible BV / Share (Annual)$1.04
Price vs S&P 500 (52W)146.30%
Year-to-Date Return-9.85%
5-Day Price Return2.22%
EPS Normalized (Annual)$-0.67
ROA (5Y Avg)-26.23%
Net Profit Margin (Annual)-84.92%
Month-to-Date Return33.40%
Cash Flow / Share (TTM)$-0.66
EBITD / Share (Annual)$-0.13
Operating Margin (Annual)-41.56%
LT Debt / Equity (Annual)0.98x
ROI (5Y Avg)-39.44%
LT Debt / Equity (Quarterly)0.98x
EPS Basic Excl Extra (TTM)$-0.85
P/TBV (Quarterly)4.68x
P/B Ratio (Annual)4.65x
Inventory Turnover (TTM)93.83x
Pretax Margin (TTM)-66.43%
Book Value / Share (Annual)$1.05
Price vs S&P 500 (13W)2.78%
Beta0.40x
P/FCF (Annual)16.81x
Revenue / Share (TTM)$1.28
ROE (TTM)-87.43%
52-Week Low$1.23
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CLLSCellectis S.A. American Depositary Shares | 2.50x | 74.59% | 43.61% | — | $4.10 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Cellectis SA is a clinical-stage biotechnology company developing gene-editing treatments for cancer and other diseases. The company's pipeline includes allogeneic CAR-T cell therapies for immuno-oncology and gene-edited stem cell products for other therapeutic areas. Its proprietary technology platform creates off-the-shelf cellular therapies with the potential for improved clinical outcomes and broader patient access.